Diabetic Macular Edema

Bausch + Lomb and Clearside Biomedical Inc. are rolling out the new therapeutic, approved by the FDA for suprachoroidal use for the treatment of macular edema associated with uveitis.

Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular edema.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

Joshua Mali, MD, talks about how the FDA approval of faricimab will change the treatment landscape for wet AMD and DME.

Genentech’s treatment of faricimab is the first and only FDA-approved medicine targeting two distinct pathways, angiopoietin (Ang)-2 and vascular endothelial growth factor (VEGF)-A, that often cause retinal diseases that may cause visual loss.

Approach shows potential as a promising second-line screening tool for patients with diabetes.

The improvement became evident during an average time of 6 months.

Consecutive intravitreal dexamethasone treatments may be beneficial for patients with DME patients who had undergone a previous vitrectomy.

In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.

The difference in visual acuities based on CST fluctuations in these patients with diabetic macular edema remained significant.

Current options, challenges in developing novel therapies.

Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.

Some studies have reported that retinal vascular permeability results in choroidal thickening, while others have reported choroidal thinning or no changes.

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

Dr. Jorge Calzada shares his methods for treating diabetic macular edema with MicroPulse Laser and anti-VEGF injections.

Confronting issues unique to aging may lead to better outcomes.

A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

MicroPulse can reduce burden of injections for patients with diffuse diabetic macular edema.

Researchers set out to identify clinical and anatomic factor-associated vision loss in eyes with treatment-naïve DME and good initial VA.

John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.

A study in the United Arab Emirates reported a possible link between adverse ocular events and a COVID-19 vaccination.

Investigators find that wearable aid offers improved mobility.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Dr. Jorge Calzada's diabetic macular edema blog dives into his successful treatment of DME with MicroPulse.

Ophthalmologists face challenges of drug delivery for retinal diseases.

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.

The impact of the COVID-19 pandemic on the management of patients with retinal disorders and considerations for how new practices may be adopted into future practice.

Dr Mariya Moosajee comments on the next generation of gene therapy for inherited retinal disease and highlights various systems under investigation.

Visual benefit is not seen during first 2 years of Protocol W study.